Dyadic Adds European Partner to Precision-Fermented Dairy Protein Pipeline

Florida biotechnology company Dyadic International has entered a development and commercial license agreement with a European partner to develop precision-fermented dairy proteins using their proprietary fermentation platform. The agreement includes development and commercial payments, licensing revenues, and economic participation upon successful commercialization. This adds to Dyadic's existing dairy portfolio, which includes cheese-making enzymes and alpha-lactalbumin under development with other partners in Europe. The company's strategy focuses on generating recurring revenue through a licensing model rather than in-house production.

The new program will progress through strain optimization, process development, and commercial scale-up, although no cash receipt or completed commercial launch has been reported to date. Dyadic's expansion into the food and nutrition market aligns with their goal of building a diversified pipeline of precision-fermented dairy proteins and enzymes using their Dapibus platform. This approach aims to enhance commercial growth and revenue across multiple stages, showcasing the company's commitment to innovation and partnership within the biotechnology industry.